Parallel (randomized) phase II evaluation of tivantinib (ARQ197) and tivantinib in combination with erlotinib in papillary renal cell carcinoma: SWOG S1107
- Przemyslaw W. Twardowski
- , Catherine M. Tangen
- , Xiwei Wu
- , Melissa R. Plets
- , Elizabeth R. Plimack
- , Neeraj Agarwal
- , Nicholas J. Vogelzang
- , Jinhui Wang
- , Shu Tao
- , Ian M. Thompson
- , Primo Lara
- Saint John's Health Center
- Fred Hutchinson Cancer Research Center
- University of Utah
- US Oncology Network
- CHRISTUS Santa Rosa Medical Center Hospital
- University of California at Davis
Research output: Contribution to journal › Article › peer-review
33
Scopus
citations